> a lifetime perpetual non-exclusive right to use and re-license said patent on what ever terms they deem acceptable.
Probably the biggest immediate positive impact would be automatically securing the rights to produce and distribute the patented good in developing nations. BigCo isn’t making much money there anyway.
Economy of scale. You make little from a large population. Or you can go Nestle level evil and straight out exploit the most in need [1]. Plenty of ways for BigCo to make money of developing nations.
> Plenty of ways for BigCo to make money of developing nations.
Making some money sure, but developing nations are not great consumer markets and BigCo isn’t making a big chunk of its profit there. It ought to be possible for BigCo to be made to accept the loss of a market they probably would neglect anyway (especially pharma) in exchange for R&D funding to give legal clearance for other organizations to serve those populations.
You wrote: <<automatically securing the rights to produce and distribute the patented good in developing nations>>.
Real question for you and others: Where do we draw the line? That is an enormously complex question!
I have an equivalent to discuss: During the COVID-19 crisis, I was bothered that the South Africa gov't was pushing so hard to get access to produce vaccines locally without paying patent licensing costs. (Without very advanced pharma manuf facils, it would be useless. Many people under estimate the complexity of producing these new mRNA vaccines, let alone distributing them safely and correctly.) South Africa is, by many measures, a middle income economy. They could absolutely affort 10-20 USD per citizen to vaccinate their population -- not so different than what EU paid for vaccines. Please do not interpret this post as "dumping on SA"!. I just want to discuss a very specific example.
Related: The Serum Institute of India (which I think is the world's largest producer by vaccine doses) eventually secured a licenses to produce and sell vaccines. (Wiki tells me three were licensed [very impressive!]: AstraZeneca/Oxford, Novavax, and Russia's Gamaleya Sputnik V.) Does anyone know the details of SI's licensing agreements?
Probably the biggest immediate positive impact would be automatically securing the rights to produce and distribute the patented good in developing nations. BigCo isn’t making much money there anyway.